Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 23 | 2020 | 62 | 4.410 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2020 | 23 | 1.630 |
Why?
|
| Muscle, Skeletal | 9 | 2019 | 512 | 1.190 |
Why?
|
| Charcot-Marie-Tooth Disease | 3 | 2020 | 8 | 1.180 |
Why?
|
| Neural Conduction | 4 | 2020 | 91 | 1.060 |
Why?
|
| Ultrasonography | 9 | 2019 | 378 | 0.950 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 7 | 0.730 |
Why?
|
| Plasma Exchange | 1 | 2020 | 14 | 0.720 |
Why?
|
| Humans | 46 | 2020 | 32082 | 0.670 |
Why?
|
| Mutation | 4 | 2019 | 485 | 0.670 |
Why?
|
| Hemifacial Spasm | 1 | 2019 | 3 | 0.670 |
Why?
|
| Trigeminal Neuralgia | 1 | 2019 | 33 | 0.650 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2018 | 1 | 0.650 |
Why?
|
| Family Health | 2 | 2017 | 78 | 0.640 |
Why?
|
| Nerve Tissue | 1 | 2018 | 2 | 0.640 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 9 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 99 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 103 | 0.640 |
Why?
|
| Immunologic Factors | 1 | 2018 | 49 | 0.620 |
Why?
|
| Middle Aged | 29 | 2020 | 11834 | 0.610 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2017 | 2 | 0.580 |
Why?
|
| Gelsolin | 1 | 2017 | 2 | 0.580 |
Why?
|
| Amyloidosis, Familial | 1 | 2017 | 2 | 0.580 |
Why?
|
| Electromyography | 3 | 2017 | 59 | 0.560 |
Why?
|
| Muscles | 1 | 2017 | 62 | 0.560 |
Why?
|
| Periventricular Nodular Heterotopia | 1 | 2016 | 1 | 0.550 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2016 | 5 | 0.550 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2016 | 3 | 0.550 |
Why?
|
| Male | 32 | 2020 | 19202 | 0.530 |
Why?
|
| Muscle Cramp | 1 | 2015 | 3 | 0.520 |
Why?
|
| Peripheral Nerves | 2 | 2019 | 62 | 0.520 |
Why?
|
| Upper Extremity | 1 | 2016 | 57 | 0.520 |
Why?
|
| Adult | 23 | 2020 | 9375 | 0.500 |
Why?
|
| Female | 31 | 2020 | 19999 | 0.480 |
Why?
|
| Aged | 21 | 2020 | 10308 | 0.450 |
Why?
|
| Brain | 1 | 2020 | 948 | 0.430 |
Why?
|
| Myasthenia Gravis | 2 | 2020 | 15 | 0.430 |
Why?
|
| Autoantibodies | 2 | 2020 | 49 | 0.420 |
Why?
|
| Neuromuscular Junction | 4 | 2018 | 66 | 0.390 |
Why?
|
| Hematoma | 1 | 2011 | 27 | 0.390 |
Why?
|
| Myography | 3 | 2018 | 6 | 0.380 |
Why?
|
| Electric Impedance | 3 | 2018 | 13 | 0.380 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2010 | 1 | 0.370 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 2 | 0.370 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 4 | 0.370 |
Why?
|
| Stroke | 2 | 2009 | 584 | 0.370 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 48 | 0.360 |
Why?
|
| Cranial Nerves | 1 | 2009 | 7 | 0.340 |
Why?
|
| Thromboembolism | 1 | 2009 | 34 | 0.320 |
Why?
|
| Immunity | 2 | 2018 | 20 | 0.320 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 3990 | 0.300 |
Why?
|
| Disease Progression | 6 | 2020 | 594 | 0.290 |
Why?
|
| Motor Neurons | 3 | 2020 | 40 | 0.280 |
Why?
|
| Case-Control Studies | 5 | 2019 | 895 | 0.280 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2006 | 1 | 0.270 |
Why?
|
| Neuroprotective Agents | 2 | 2020 | 27 | 0.260 |
Why?
|
| Sural Nerve | 2 | 2019 | 28 | 0.260 |
Why?
|
| Blepharoptosis | 1 | 2005 | 1 | 0.260 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 18 | 0.250 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 22 | 0.250 |
Why?
|
| Myelin P0 Protein | 2 | 2019 | 4 | 0.250 |
Why?
|
| Adolescent | 5 | 2020 | 3568 | 0.240 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 473 | 0.240 |
Why?
|
| Median Nerve | 2 | 2017 | 51 | 0.230 |
Why?
|
| Ceftriaxone | 2 | 2014 | 14 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.210 |
Why?
|
| Research Design | 2 | 2016 | 315 | 0.210 |
Why?
|
| Cognition Disorders | 1 | 2006 | 385 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 297 | 0.210 |
Why?
|
| Evoked Potentials, Motor | 2 | 2018 | 8 | 0.190 |
Why?
|
| Young Adult | 5 | 2020 | 2665 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 322 | 0.190 |
Why?
|
| Plasmapheresis | 1 | 2020 | 11 | 0.180 |
Why?
|
| Agrin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Intermediate Filaments | 1 | 2020 | 4 | 0.180 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2020 | 10 | 0.180 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 95 | 0.180 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 30 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Inpatients | 1 | 2020 | 83 | 0.170 |
Why?
|
| Time Factors | 3 | 2020 | 2145 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2019 | 6 | 0.170 |
Why?
|
| Myositis, Inclusion Body | 1 | 2019 | 7 | 0.160 |
Why?
|
| Pedigree | 1 | 2019 | 140 | 0.160 |
Why?
|
| Tracheostomy | 1 | 2019 | 28 | 0.160 |
Why?
|
| Sample Size | 1 | 2018 | 38 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2018 | 31 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2019 | 246 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.160 |
Why?
|
| Family | 1 | 2019 | 117 | 0.160 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 42 | 0.150 |
Why?
|
| Psychometrics | 1 | 2018 | 137 | 0.150 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 4 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1542 | 0.140 |
Why?
|
| Phenotype | 1 | 2019 | 632 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 72 | 0.140 |
Why?
|
| Extremities | 1 | 2017 | 50 | 0.140 |
Why?
|
| Scapula | 1 | 2017 | 18 | 0.140 |
Why?
|
| Wrist | 1 | 2017 | 48 | 0.140 |
Why?
|
| Neuromuscular Agents | 1 | 2017 | 29 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 39 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 299 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 770 | 0.140 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 28 | 0.130 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2016 | 3 | 0.130 |
Why?
|
| Huntington Disease | 1 | 2016 | 15 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 146 | 0.130 |
Why?
|
| Ulnar Neuropathies | 1 | 2015 | 17 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2015 | 62 | 0.120 |
Why?
|
| Inflammation | 1 | 2018 | 529 | 0.120 |
Why?
|
| Myelin Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1325 | 0.120 |
Why?
|
| Vital Capacity | 3 | 2018 | 39 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 516 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 510 | 0.110 |
Why?
|
| Plant Oils | 1 | 2013 | 16 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 946 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 244 | 0.100 |
Why?
|
| Age of Onset | 2 | 2016 | 94 | 0.100 |
Why?
|
| African Americans | 1 | 2019 | 1424 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2013 | 185 | 0.100 |
Why?
|
| Muscular Atrophy | 1 | 2011 | 71 | 0.090 |
Why?
|
| Motor Neuron Disease | 1 | 2010 | 3 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 2010 | 14 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2019 | 1816 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 765 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2020 | 525 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 149 | 0.080 |
Why?
|
| Apoptosis | 1 | 2010 | 353 | 0.080 |
Why?
|
| Peripheral Nervous System | 1 | 2008 | 6 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2019 | 3505 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 53 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 22 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 472 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 11 | 0.070 |
Why?
|
| Electrodiagnosis | 2 | 2017 | 42 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2006 | 26 | 0.070 |
Why?
|
| Animals | 5 | 2018 | 7510 | 0.060 |
Why?
|
| Epilepsy | 1 | 2006 | 82 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1020 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 876 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 2282 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1538 | 0.050 |
Why?
|
| Time | 1 | 2020 | 23 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 1128 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 629 | 0.050 |
Why?
|
| Risk Factors | 1 | 2009 | 3880 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 28 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2263 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2020 | 98 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3304 | 0.040 |
Why?
|
| Forearm | 1 | 2019 | 43 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 105 | 0.040 |
Why?
|
| Diaphragm | 1 | 2018 | 38 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2010 | 462 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 581 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 989 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 15 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2017 | 28 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 881 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2017 | 37 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 547 | 0.040 |
Why?
|
| Head | 1 | 2017 | 51 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1496 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 203 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 23 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1165 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 60 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 100 | 0.030 |
Why?
|
| Nutrition Therapy | 1 | 2013 | 5 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2439 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 110 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 534 | 0.030 |
Why?
|
| United States | 1 | 2020 | 3975 | 0.020 |
Why?
|
| Semaphorins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Growth Cones | 1 | 2010 | 2 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 10 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 18 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2010 | 62 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 26 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 129 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 107 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 190 | 0.020 |
Why?
|
| Ganglia, Spinal | 1 | 2010 | 64 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 93 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 279 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 827 | 0.020 |
Why?
|
| Riluzole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 246 | 0.020 |
Why?
|
| Hindlimb | 1 | 2007 | 53 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 261 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2007 | 119 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2007 | 249 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 324 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 1187 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 2474 | 0.010 |
Why?
|